FDA Clears 31 New Molecular Entities In 2004, Up 10 From Previous Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NME rebound in 2004? Final count is 31 versus 21 in 2003 – however, 2004 tally includes several atypical new molecular entities. Top 10 pharma companies hold small share of the total, with no companies clearing more than two NMEs during the year. Over 20% of the approvals came in the last two weeks of December
You may also be interested in...
Omacor Potential To Increase LDL Cholesterol Limits Use To Severe Patients
Omacor indication limited to severe hypertriglyceridemia because of increased LDL-cholesterol associated with the drug, FDA review documents indicate. Ross was unable to support cardioprotective benefit or reduction of risk of pancreatitis; omega-3 fatty acids, also marketed in U.S. as a dietary supplement, is approved for cardiovascular outcomes in other countries
Omacor Potential To Increase LDL Cholesterol Limits Use To Severe Patients
Omacor indication limited to severe hypertriglyceridemia because of increased LDL-cholesterol associated with the drug, FDA review documents indicate. Ross was unable to support cardioprotective benefit or reduction of risk of pancreatitis; omega-3 fatty acids, also marketed in U.S. as a dietary supplement, is approved for cardiovascular outcomes in other countries
Diabetes Drug Advances Are Highlight Of NMEs Pending In 2005
Highlights of NME class of 2005 could be advances in diabetes, with Lilly/Amylin’s exenatide and Amylin’s Symlin currently being reviewed and Pfizer’s inhaled insulin Exubera slated for filing early in the year. Other major pending NMEs include J&J’s dapoxetine for premature ejaculation and Solvay’s irritable bowel syndrome agent Calmactin (cilansetron)